Proteomic profiling during atherosclerosis progression using SELDI-TOF-MS: Effect of darbepoetin treatment

Acta Histochemica

Volumn 112, Issue 5, 2010, Pages 432-443

  Dursun, Evrim ^a   Monari, Emanuela ^b   Cuoghi, Aurora ^b   Bergamini, Stefania ^b   Ozben, Beste ^c   Suleymanlar, Gultekin ^a   Tomasi, Aldo ^b   Ozben, Tomris ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Apolipoprotein E deficient mice; Atherosclerosis; Darbepoetin; Proteomics; SELDI TOF MS

Indexed keywords

APOLIPOPROTEIN E; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; ION EXCHANGE CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; REVERSED PHASE LIQUID CHROMATOGRAPHY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

MUS;

EID: 77955272478     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2009.04.003     Document Type: Article

References (32)

1. Almofti M.R., Huang Z., Yang P., Rui Y., Yang P. Proteomic analysis of rat aorta during atherosclerosis induced by high cholesterol diet and injection of vitamin D3. Clin Exp Pharmacol Physiol 2006, 33:305-309.
2. Arcasoy M.O. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008, 141:14-31.
3. Arrell D.K., Neverova I., Van Eyk J.E. Cardiovascular proteomics: evolution and potential. Circ Res 2001, 88:763-773.
4. Aviram M., Volkova N., Coleman R., Dreher M., Reddy M.K., Ferreira D., et al. Pomegranate phenolics from the peels, arils, and flowers are antiatherogenic: studies in vivo in atherosclerotic apolipoprotein e-deficient (E 0) mice and in vitro in cultured macrophages and lipoproteins. J Agric Food Chem 2008, 56:1148-1157.
5. Blanco-Colio L.M., Martin-Ventura J.L., Vivanco F., Michel J.B., Meilhac O., Egido J. Biology of atherosclerotic plaques: what we are learning from proteomic analysis. Cardiovasc Res 2006, 72:18-29.
6. Cleland J.G., Coletta A.P., Clark A.L., Velavan P., Ingle L. Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: darbepoetin alfa study, ECHOS, and ASCOT-BPLA. Eur J Heart Fail 2005, 7:937-939.
7. Cleland J.G., Sullivan J.T., Ball S., Horowitz J.D., Agoram B., Rosser D., et al. Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation. J Cardiovasc Pharmacol 2005, 46:155-161.
8. Coleman L.S. Atherosclerosis may be caused by inadequate levels of turbulence and mixing. World J Surg 2006, 30:638-639.
9. Coleman R., Hayek T., Keidar S., Aviram M. A mouse model for human atherosclerosis: long-term histopathological study of lesion development in the aortic arch of apolipoprotein E-deficient (E0) mice. Acta Histochem 2006, 108:415-424.
10. Dursun E, Ozben B, Monari E, Cuoghi A, Tomasi A, Ozben T. Proteomic profiling in apolipoprotein E-deficient mice during atherosclerosis progression. Acta Histochem, 2009; Feb 19. [Epub ahead of print]. doi:10.1016/j.acthis.2008.10.007.
11. Fabrizio Rodella L., Bonomini F., Rezzani R., Tengattini S., Hayek T., Aviram M., et al. Atherosclerosis and the protective role played by different proteins in apolipoprotein E-deficient mice. Acta Histochem 2007, 109:45-51.
12. Faraz H.A., Zafar S.F., Ghali J.K. Anemia and the potential role of erythropoiesis-stimulating agents in heart failure. Curr Heart Fail Rep 2008, 5:83-90.
13. Fuhrman B., Volkova N., Coleman R., Aviram M. Grape powder polyphenols attenuate atherosclerosis development in apolipoprotein E deficient (E0) mice and reduce macrophage atherogenicity. J Nutr 2005, 135:722-728.
14. Hayek T., Hussein K., Aviram M., Coleman R., Keidar S., Pavoltzky E., et al. Macrophage foam-cell formation in streptozotocin-induced diabetic mice: stimulatory effect of glucose. Atherosclerosis 2005, 183:25-33.
15. Hong H., Dragan Y., Epstein J., Teitel C., Chen B., Xie Q., et al. Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS). BMC Bioinformatics 2005, 6(Suppl. 2):S5.
16. Katz S.D., Mancini D., Androne A.S., Hryniewicz K. Treatment of anemia in patients with chronic heart failure. J Card Fail 2004, 10:S13-S16.
17. Kim W.H., Choi C.H., Kang S.K., Kwon C.H., Kim Y.K. Ceramide induces non-apoptotic cell death in human glioma cells. Neurochem Res 2005, 30:969-979.
18. Lam L., Lind J., Semsarian C. Application of proteomics in cardiovascular medicine. Int J Cardiol 2006, 108:12-19.
19. Mayr M., Chung Y.L., Mayr U., Yin X., Ly L., Troy H., et al. Proteomic and metabolomic analyses of atherosclerotic vessels from apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and energy metabolism. Arterioscler Thromb Vasc Biol 2005, 25:2135-2142.
20. Mayr M., Madhu B., Xu Q. Proteomics and metabolomics combined in cardiovascular research. Trends Cardiovasc Med 2007, 17:43-48.
21. Mayr M., Mayr U., Chung Y.L., Yin X., Griffiths J.R., Xu Q. Vascular proteomics: linking proteomic and metabolomic changes. Proteomics 2004, 4:3751-3761.
22. Murphy C.L., McMurray J.J. Approaches to the treatment of anaemia in patients with chronic heart failure. Heart Fail Rev 2008, 13:431-438.
23. Napoli C., Palinski W., Di Minno G., D'Armiento F.P. Determination of atherogenesis in apolipoprotein E-knockout mice. Nutr Metab Cardiovasc Dis 2000, 10:209-215.
24. Palazzuoli A., Silverberg D.S., Iovine F., Calabro A., Campagna M.S., Gallotta M., et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007, 154:645. (e649-615).
25. Rosenblat M., Volkova N., Coleman R., Almagor Y., Aviram M. Antiatherogenicity of extra virgin olive oil and its enrichment with green tea polyphenols in the atherosclerotic apolipoprotein-E-deficient mice: enhanced macrophage cholesterol efflux. J Nutr Biochem 2008, 19:514-523.
26. Rosenblat M., Volkova N., Coleman R., Aviram M. Anti-oxidant and anti-atherogenic properties of liposomal glutathione: studies in vitro, and in the atherosclerotic apolipoprotein E-deficient mice. Atherosclerosis 2007, 195:e61-e68.
27. Rosenblat M., Volkova N., Coleman R., Aviram M. Pomegranate byproduct administration to apolipoprotein e-deficient mice attenuates atherosclerosis development as a result of decreased macrophage oxidative stress and reduced cellular uptake of oxidized low-density lipoprotein. J Agric Food Chem 2006, 54:1928-1935.
28. Silverberg D.S., Wexler D., Iaina A., Schwartz D. The role of correction of anaemia in patients with congestive heart failure: a short review. Eur J Heart Fail 2008, 10:819-823.
29. Silverberg D.S., Wexler D., Iaina A., Schwartz D. The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions. Clin Exp Nephrol 2009, 13(2):101-106.
30. Tabibiazar R., Wagner R.A., Deng A., Tsao P.S., Quertermous T. Proteomic profiles of serum inflammatory markers accurately predict atherosclerosis in mice. Physiol Genomics 2006, 25:194-202.
31. Wuttge D.M., Sirsjo A., Eriksson P., Stemme S. Gene expression in atherosclerotic lesion of ApoE deficient mice. Mol Med 2001, 7:383-392.
32. van Veldhuisen D.J., Dickstein K., Cohen-Solal A., Lok D.J., Wasserman S.M., Baker N., et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007, 28:2208-2216.